Bristol-Myers Squibb Company
BMY
Jodie situation report
Bristol-Myers Squibb Company's move is being confirmed by its market group.
BMY accounts for 0.1% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
MRK, ACAD, EXEL moved materially before BMY. BMY crossed its material path threshold at 10:40 ET. NBIX, BMRN, REGN followed.
8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABBV begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind BMY
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZBIOZenas BioPharma, Inc.partnerFeb 11, 2026 ▾
“The IDMC recommended that the other two Phase III trials, Librexia AF for patients with atrial fibrillation AF and Librexia STROKE for secondary stroke prevention, continue as planned, with topline data expected in 2026.”
BNTXBioNTech SEpartnerOct 30, 2025 ▾
“BioNTech In June 2025, BMS and BioNTech entered into a global strategic collaboration for the co-development and co-commercialization of pumitamig (BNT327/BMS986545), a bispecific antibody targeting PD-L1 and VEGF-A, which is currently being evaluated in a Ph…”
Depended on by
PRTAProthena Corporation plcpartnerMay 7, 2026 ▾
“Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in partnership with Roche, coramitug currently being evaluated in the Phase 3 CLEOPATTRA clinica…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 25 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
BMY is currently a Early Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.